Does Rallies show Form 4 insider transactions for ABOS?

Yes. Rallies tracks ABOS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ABOS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABOS. It does not provide personalized investment advice.

ABOS (Acumen Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Acumen Pharmaceuticals, Inc. Common Stock (ABOS) is a publicly traded Healthcare sector company. As of May 21, 2026, ABOS trades at $2.37 with a market cap of $157.46M and a P/E ratio of -1.16. ABOS moved +9.22% today. Year to date, ABOS is +18.69%; over the trailing twelve months it is +121.70%. Its 52-week range spans $0.86 to $3.60. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces ABOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ABOS stock inside the company?

Recent ABOS insider activity includes Meisner Derek M sold 2.09K, Meisner Derek M sold 9.41K, Meisner Derek M sold 2.67K, Meisner Derek M sold 15.09K, and Meisner Derek M sold 5.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ABOS Key Metrics

Key financial metrics for ABOS
Metric	Value
Price	$2.37
Market Cap	$157.46M
P/E Ratio	-1.16
EPS	$-2.00
Dividend Yield	0.00%
52-Week High	$3.60
52-Week Low	$0.86
Volume	1.40K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-121.33M
Gross Margin	0.00%

Recent ABOS Insider Trades

Meisner Derek M sold 2.09K (~$6.81K) on Mar 6, 2026.
Meisner Derek M sold 9.41K (~$28.31K) on Feb 27, 2026.
Meisner Derek M sold 2.67K (~$8.02K) on Jan 28, 2026.
Meisner Derek M sold 15.09K (~$45.26K) on Jan 26, 2026.
Meisner Derek M sold 5.63K (~$10.72K) on Jan 23, 2026.

Latest ABOS News

Acumen Pharmaceuticals Confirms Phase 2 Sabirnetug Trial on Track, Data by Late 2026 — May 12, 2026
Acumen Pharmaceuticals closes $35.8M financing, completes ALTITUDE-AD enrollment — Mar 26, 2026
Acumen raises $35.75M for EBD program, sabirnetug Phase 2 readout due late 2026 — Mar 26, 2026
Acumen to Present JCR-Backed Sabirnetug Brain Delivery and Biomarker Data at AD/PD — Mar 3, 2026

ABOS Analyst Consensus

2 analysts cover ABOS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about ABOS

Who is trading ABOS stock inside the company?: Recent ABOS insider activity includes Meisner Derek M sold 2.09K, Meisner Derek M sold 9.41K, Meisner Derek M sold 2.67K, Meisner Derek M sold 15.09K, and Meisner Derek M sold 5.63K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ABOS?: Yes. Rallies tracks ABOS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ABOS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABOS. It does not provide personalized investment advice.